NextGen BRCA Somatic, FFPE tissue
Sample Type
Recommended for
Report
Next-generation sequencing (NextGen) of BRCA somatic mutations in formalin-fixed paraffin-embedded (FFPE) tissue samples plays a pivotal role in identifying specific genetic alterations within the BRCA genes. This molecular analysis is particularly relevant in the context of PARP inhibitor therapy. PARP inhibitors are a class of targeted cancer treatments that show effectiveness in patients with BRCA mutations, as these mutations impair DNA repair mechanisms. By assessing somatic mutations in the BRCA genes using NextGen sequencing on FFPE tissue samples, healthcare providers can identify actionable genetic changes that inform the use of PARP inhibitor therapies. This personalized approach enhances treatment decisions and potentially improves outcomes for individuals with cancers linked to BRCA mutations.
Price : ₹ 22,000
This test measures specific genetic mutations in the BRCA genes. Mutations in these genes increase the risk of developing certain types of cancer, particularly breast and ovarian cancer.
• To identify mutations in the BRCA genes that may increase the risk of developing certain types of cancer
• To determine eligibility for targeted therapies, such as PARP inhibitor therapy
• To assess the response to treatment in patients receiving PARP inhibitor therapy
• To provide a personalised risk assessment for individuals with a family history of breast or ovarian cancer
This test is recommended for individuals who
- have a personal or family history of breast or ovarian cancer,
- have already been diagnosed with breast or ovarian cancer and want to determine if they have an inherited mutation,
- are considering or undergoing targeted therapies, such as PARP inhibitor therapy, or
- have a family member with a known BRCA mutation.
Abnormal results may indicate the presence of specific genetic mutations that increase the risk of developing certain types of cancer.
A sample of tissue containing the tumour, fixed in formalin and embedded in paraffin, will be required for testing. The test uses a method called Next-Generation Sequencing (NGS) to analyse the specific BRCA gene mutations.
